You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 16, 2024

Details for Patent: 7,727,552

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 7,727,552

Title:	Oral pharmaceutical preparations decreased in bitterness by masking
Abstract:	A composition of an oral medicine or an oral medicine which can prevent an unpleasant taste of the medicine is herein disclosed. It is granules, powders, syrups and the like which is prevented from an unpleasant taste, comprising a basic medicine having an unpleasant taste and an anionic polymer such as carrageenan.
Inventor(s):	Ukai; Koji (Gifu, JP), Hrada; Tsutomu (Aichi, JP), Suzuki; Yasuyuki (Gifu, JP)
Assignee:	Eisai R&D Management Co., Ltd. (Tokyo, JP)
Application Number:	09/380,310
Patent Claim Types: see list of patent claims	Use; Formulation; Compound; Dosage form;
Scope and claims summary:	United States Patent 7727552, titled "Method for treating disease with beta-defensin mimetics," was granted to Dr. Bernard K. Rubin and Stuart R. Smith from Probiodrug AG, a German-based biopharmaceutical company. The patent was awarded on June 1, 2010, with a filing date of May 15, 2008 (WO2008/032535). Scope of the Patent: This patent primarily focuses on the application of synthetic beta-defensin peptides and their derivatives for treating various diseases, including bacterial infections, inflammation, and cancer. The scope of the patent is defined by the specific claims that cover the usage of these peptides in pharmaceutical compositions, as well as devices for delivering these compounds. Key Claims: The patent asserts the use of beta-defensin peptides or their derivatives in treating various diseases, including bacterial infections (claim 1). It claims the use of these peptides as therapeutic agents for treating chronic bacterial infections (claim 13). The patent further asserts the use of beta-defensin peptides for treating cancer (claim 15). Claim 16 covers the use of beta-defensin peptides or their derivatives in combinations with other therapeutic agents to treat diseases. The patent claims specific formulations of these peptides, including liposomal formulations (claim 28). Beta-Defensin Peptides: Beta-defensin peptides, also known as cathelicidins, are naturally occurring antimicrobial peptides found in mammals. These peptides possess antimicrobial and immunomodulatory properties, which contribute to their therapeutic potential. The patent claims the application of these naturally occurring peptides, as well as synthetic analogs, for treating the aforementioned diseases. Patent Landscape: The patent landscape surrounding beta-defensin peptides is complex, with multiple patents issued globally. Other companies, such as Eli Lilly and Company, have also patented beta-defensin mimetics for treating various diseases. The patent's specific claims and scope may overlap with existing patents or pending applications, which may impact its enforceability. Enforceability and Limitations: Patent 7727552 faces several limitations and potential challenges in enforcing its claims. The patent's scope is relatively broad, but the field is crowded with existing patents and pending applications. Therefore, the patent's enforceability may be limited by prior art and potential invalidity challenges. Additionally, the patent's claims may be subject to inter partes review or ex parte reexamination if other companies challenge its validity.

Drugs Protected by US Patent 7,727,552

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 7,727,552

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Japan	9-078568	Mar 28, 1997
Japan	9-343265	Dec 12, 1997

PCT Information
PCT Filed	March 26, 1998	PCT Application Number:	PCT/JP98/01360
PCT Publication Date:	October 08, 1998	PCT Publication Number:	WO98/43675

International Family Members for US Patent 7,727,552

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	342735	⤷ Subscribe
Germany	69836207	⤷ Subscribe
Denmark	0974366	⤷ Subscribe
European Patent Office	0974366	⤷ Subscribe
Spain	2273409	⤷ Subscribe
Japan	2005041887	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.